Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A pharmaceutical aerosol formulation comprising particles of (a) formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof and (b) mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof dispersed in a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, and a bulking agent having a mass median diameter of less than one micron.

2. (Original) A pharmaceutical aerosol formulation according to claim 1, wherein the formoterol is in the form of formoterol fumarate.

3. (Original) A pharmaceutical aerosol formulation according to claim 2, wherein the formoterol is in the form of formoterol fumarate dihydrate.

4. (Currently amended) A phamaceutical aerosol formulation ~~any one of claims 1 to 3~~ of claim 1, wherein the mometasone is in the form of mometasone furoate.

5. (Currently amended) A pharmaceutical aerosol formulation according to ~~any one of claims 1 to~~ 4 claim 1, wherein the formoterol is present in an amount of about 0.06 to 0.60 mg per ml.

6. (Currently amended) A pharmaceutical aerosol formulation according to ~~any one of claims 1 to 5~~ claim 1, wherein the mometasone is present in amount of about 0.5 to 15.0 mg per ml.

7. (Currently amended) A pharmaceutical aerosol formulation according to ~~any one of claims 1 to 6~~ claim 1, wherein the bulking agent is selected from groups consisting of ascorbic acid, saccharides, polysaccharides, amino acids, organic and inorganic salts, urea and propyliodone.

8. (Original) A pharmaceutical aerosol formulation according to claim 7, wherein the bulking agent is selected from lactose, DL-alanine, glucose, D-galactose, D(+)trehalose dihydrate, sucrose, maltose, D(+)raffinose pentahydrate, sodium saccharin, starches, modified

celluloses, dextrins, dextrans, glycine, sodium chloride, calcium carbonate, sodium tartrate and calcium lactate.

9. (Currently amended) A pharmaceutical aerosol formulation according to claim 7 ~~or claim 8~~, wherein the bulking agent is lactose.

10. (Currently amended) A pharmaceutical aerosol formulation according to ~~any one of claims 1 to 9~~ claim 1, wherein the weight ratio of formoterol to bulking agent is in the range 1:0.1 to 1:30.

11. (Currently amended) A pharmaceutical aerosol formulation according to ~~any one of claims 1 to 10~~ claim 1, wherein the bulking agent has a mass median diameter of not more than 300 nm.

12. (Currently amended) A pharmaceutical aerosol formulation according to ~~any one of claims 1 to 11~~ claim 1, wherein the formulation further comprises a surfactant.

13. (Currently amended) A pharmaceutical aerosol formulation according to ~~any one of claims 1 to 12~~ claim 1, wherein the formulation further comprises ethanol.

14. (Original) A pharmaceutical aerosol formulation according to claim 13, wherein ethanol is present in amount of from 0.1 to 5% by weight of the formulation.

15. (Currently amended) A dispenser comprising an aerosol vial equipped with a dispensing valve, said aerosol vial containing a formulation according to ~~any one of claims 1 to 14~~ claim 1.

16. (Original) A dispenser according to claim 16, wherein an interior surface of the aerosol vial is coated with a fluorocarbon polymer.

17. (Original) A method of preparing a formulation according to claim 1, the method comprising the steps of (i) forming a slurry of bulking agent with a component of the formulation; (ii) subjecting the slurry to high pressure homogenization; and (iii) combining the resulting slurry with other components of the aerosol formulation.